SkinBioTherapeutics PLC (AIM:SBTX) said trading has started positively for the new financial year and the board continues to expect results to be in line with market expectations.
The company said, in an update ahead of the company’s annual general meeting, it still anticipates reporting revenue of £6.2 million and adjusted EBITDA of £0.7 million for the year ending 30 June, 2026. The board said this outlook reflects the current trading performance across the group.
SkinBioTherapeutics, meanwhile, also published a question-and-answer document within the shareholder circulars section of the company’s website.
A week ago, in its results statement, the company said the progress made in 2025 has laid the groundwork for further expansion. Management expects increased High Street exposure for its AxisBiotix products through Superdrug and the first wave of cosmetic formulations containing Zenakine, the Croda-branded version of its SkinBiotix technology, to support growth through the year.
Results for the 12 months to June showed revenue rising 284% to £4.6 million, driven by direct sales of AxisBiotix, early royalty income from Zenakine, a full year of Dermatonics trading and nine months of revenue from Bio-Tech Solutions, acquired in late 2024.
Cash at year-end increased to £4.8 million, supported by inflows from acquired businesses and fundraisings totalling £5.8 million across August 2024 and June 2025.